

## P&T Motion History ADHD

Drugs reviewed	Motion	Date reviewed	Scan accepted as adequate update	Reiteration of prior motion	Decision
<p><b><u>Amphetamines:</u></b>  <b>amphetamine</b></p> <ul style="list-style-type: none"> <li>• <b>Adzenys XR-ODT</b></li> <li>• <b>Dyanavel XR</b></li> <li>• <b>Evekeo</b></li> </ul> <p>dextroamphetamine  lisdexamfetamine  methamphetamine  mixed amphetamine salts</p> <p><b><u>Methylphenidates:</u></b>  dexmethylphenidate  methylphenidate transdermal film  methylphenidate:</p> <ul style="list-style-type: none"> <li>• <b>Aptensio XR</b></li> <li>• <b>QuilliChew ER</b></li> </ul> <p><b><u>Non-Stimulants:</u></b>  atomoxetine  clonidine  guanfacine</p>	<p>After considering the evidence of safety, efficacy and special populations for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), I move that methylphenidate based and amphetamine based agents of both long and short acting formulations are safe and efficacious. A long and short acting formulation of each stimulant should be preferred drugs on the Washington State Preferred Drug List. No single stimulant medication is associated with fewer adverse events in special populations. The stimulants listed above shall not be subject to therapeutic interchange on the Washington Preferred Drug List.</p> <p>After considering the evidence of safety efficacy and special populations for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), I move that the non-stimulant atomoxetine is safe and efficacious and should be included as a preferred drug on the Washington State Preferred Drug List.</p> <p>After considering the evidence of safety efficacy and special populations for the treatment of Attention Deficit Hyperactivity</p>	<p>June 21, 2017</p>	<p>Yes  Figuroa  Flatebo</p>	<p>No</p>	<p>Passed unanimous</p>

**BOLD** = now eligible this expanded scan

\*new drug identified in scan not eligible for inclusion on PDL.

**P&T Motion History**  
**ADHD**

	<p>Disorder (ADHD), I move that the alpha agonists clonidine and guanfacine are safe and efficacious and that both of these agents should be included as a preferred drug on the Washington State Preferred Drug List.</p> <p>Motion: Figueroa 2<sup>nd</sup>: Schwilke</p>				
--	---	--	--	--	--

**BOLD** = now eligible this expanded scan

\*new drug identified in scan not eligible for inclusion on PDL.